Welcome to our dedicated page for American Well SEC filings (Ticker: AMWL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on American Well's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into American Well's regulatory disclosures and financial reporting.
American Well Corp (AMWL) reported that its Chief Financial Officer Mark Hirschhorn sold 10,751 shares of Class A common stock on September 1, 2026 at $11.80 per share. According to the disclosure, this automatic sell to cover transaction was executed solely to pay taxes on vested restricted stock units, and he continued to hold 228,188 shares directly afterward.
American Well Corp (AMWL) reports that Phyllis Gotlib, President, International, sold 3,573 shares of Class A common stock on September 1, 2026 at $11.80 per share. According to the company’s disclosure, this automatic “sell to cover” sale was used solely to pay tax owed on vested restricted stock units and was not a discretionary trade.
After the transactions, she holds 149,181 shares directly and an additional 114,920 shares indirectly through her husband. No Rule 10b5-1 trading plan is reported for these transactions.
American Well Corp (AMWL) discloses that Chief Accounting Officer Paul Francis McNeice sold 112 shares of Class A Common Stock on September 1, 2026 at $11.80 per share. According to the company’s disclosure, the automatic “sell to cover” sale was made solely to pay tax liability from vested restricted stock units, and McNeice now holds 9,739 shares directly.
American Well Corp (AMWL) received a Form 144 notice that officer Mark Hirschhorn intends to sell up to 10,751 shares of Class A Common Stock through Morgan Stanley on or about 09/01/2026. The filing notes this is an automatic “sell to cover” transaction to satisfy tax liabilities from restricted stock unit vesting, not a discretionary trade.
American Well Corp (AMWL) reports that officer Phyllis Gotlib has filed a Rule 144 notice covering a proposed sale of 3,573 shares of Class A common stock through Morgan Stanley, with an indicated aggregate market value of $42,173.19, expected on 09/01/2026 on the NYSE.
The securities relate to the vesting of restricted stock units. The filer states the transaction is an automatic “sell to cover” to pay tax liabilities from RSU vesting and does not represent a discretionary trade. In the prior three months, the filer sold 6,677 shares for $62,306.43 on 07/01/2026 and 3,573 shares for $34,797.09 on 06/01/2026.
Senvest Management, LLC and Richard Mashaal report beneficial ownership of 1,329,057 shares of American Well Corp Class A Common Stock. This represents 8.8% of the Class A shares, based on 15,061,188 shares outstanding as of April 24, 2026, from the company’s Form 10-Q. The shares are held through Senvest Master Fund, LP and Senvest Technology Partners Master Fund, LP, over which Senvest Management acts as investment manager and Mr. Mashaal is managing member. Voting and dispositive powers are reported as shared, with no sole voting or dispositive power. The reporting persons state that the filing does not by itself constitute an admission of beneficial ownership.
American Well Corporation reported lower revenue but a much smaller loss for the quarter ended June 30, 2026. Revenue fell 27% year over year to $52.0 million, driven mainly by a drop in platform subscription fees (to $25.7 million) and “other” services and Carepoint device revenue, partly offset by higher visit revenue of $24.4 million.
Total costs and operating expenses declined 33% to $61.6 million as management reduced headcount across functions and cut consulting, marketing, and legal spend. Net loss attributable to Amwell narrowed to $9.9 million from $19.7 million, improving loss per share to $0.59 from $1.24. Adjusted EBITDA improved to a loss of $1.2 million from $4.7 million. For the first half of 2026, net loss attributable to Amwell was $20.8 million versus $38.4 million a year earlier.
Operating cash flow turned positive at $9.7 million for the six-month period, compared with a $29.8 million outflow in 2025, and cash, cash equivalents and restricted cash rose to $196.7 million. Results also reflect a $3.4 million impairment from abandoning the corporate headquarters right-of-use asset and a $7.0 million gain from contingent consideration on a prior divestiture. Client usage softened, with 1.9 million visits in the first half of 2026 versus 2.5 million a year earlier, and a single client represented 65% of accounts receivable, underscoring concentration risk.
American Well Corporation reported Q2 2026 revenue of $52.0 million, at the top of its guidance range but below $70,898 thousand a year earlier. Subscription revenue was $25.7 million and Amwell Medical Group visit revenue $24.4 million, with 0.8 million total visits. Gross margin was 53%. Net loss was ($9.6) million, improving from $10.3 million in Q1 2026, and adjusted EBITDA narrowed to a ($1.2) million loss from $3.1 million.
The company noted operating cash inflows in the first half of 2026 and highlighted having no debt. For 2026, Amwell now guides revenue to $200–$205 million, up from $195–$205 million, and expects adjusted EBITDA of a ($9)–($7) million loss, improved from a ($16)–($12) million loss range. Q3 2026 guidance calls for revenue of $46–$48 million and adjusted EBITDA of a ($5)–($3) million loss, while reiterating an objective of positive cash flow from operations in Q4 2026.
American Well Corporation changed its external auditor. On July 14, 2026, the Audit Committee dismissed PricewaterhouseCoopers LLP as the independent registered public accounting firm and appointed BDO USA, P.C. as the new independent registered public accounting firm.
American Well states that PwC’s audit reports on the company’s financial statements for the fiscal years ended December 31, 2025 and 2024 contained no adverse opinions, disclaimers, or qualifications and that there were no disagreements or reportable events under Item 304(a) of Regulation S‑K during those periods and through July 14, 2026. PwC has been asked to provide a letter to the SEC regarding these disclosures, filed as Exhibit 16.1 and dated July 20, 2026.
American Well Corporation reappointed Stephen Schlegel as a Class III director on July 11, 2026, for a term expiring at the company’s 2029 annual meeting of stockholders. Shortly before this, on July 8, 2026, he resigned as a Class II director.
The company states that his resignation and reappointment were undertaken solely to rebalance the three director classes so they are approximately equal in size, as required by NYSE listing standards, and not due to any disagreement over operations, policies, or practices. His committee assignments and compensation arrangements remain unchanged, with further background information referenced in the definitive proxy statement on Schedule 14A filed on April 24, 2026.